Disappointingly, the KEAPSAKE trial, a Phase 2, randomized, multicenter, double-blind study of CB-839 with pembrolizumab and chemotherapy versus placebo with pembrolizumab and chemotherapy for first line treatment of metastatic KEAP1/NRF2-mutant NSCLC was terminated early due to lack of clinical efficacy. Here, KEAP1 is linked to non-small cell lung carcinoma.